ASCO 2026: Key Pharma Abstracts And Our Take On The Data

Research evidence excerpt

ASCO 2026: Key Pharma Abstracts And Our Take On The Data

TD SECURITIES (USA) LLC QUICK TAKE: CONFERENCE TAKEAWAY

May 22, 2026

■Pharmaceuticals/Major ASCO 2026: Key Pharma Abstracts And Our

Take On The Data

Steve Scala, R.Ph., CFA THE TD COWEN INSIGHT

617 946 3923

ASCO abstracts were released last night. Below we highlight key data for large cap Pharma

stephen.scala@tdsecurities.com

and provide our take on the results. The most meaningful data came from ABBV, AZN, BMY,

Michael Nedelcovych, Ph.D. JNJ, and MRK. Late-breaking ASCO abstracts will be released during the conference, which

617 946 3744 begins May 29 in Chicago.

michael.nedelcovych@tdsecurities.com

Chris LoBianco Below we highlight 10 regular abstracts important to large cap Pharma, most of which outline

617 946 3734 early data for notable pipeline candidates. Late-breaking ASCO abstracts, including those

chris.lobianco@tdsecurities.com highlighted in this note, will be released after the start of the conference. Next week, to

Paul Kuhn, Ph.D. provide feedback on the data below and set expectations for the late-breakers, the TD Cowen

646 562 1328 Pharma and Biotech teams are hosting three KOL calls, each with an expert in lung cancer

paul.kuhn@tdsecurities.com (Tuesday, 10:30-11:30am ET), breast cancer (Wednesday, 10:30-11:30am ET), and multiple

myeloma (Thursday, 10:30-11:30am ET). Contact your TD Cowen salesperson for details.

AbbVie (ABBV; Buy, $214.50)

Abstract 7508 - Etentamig in patients with relapsed/refractory multiple myeloma (RRMM) with

prior exposure to B-cell maturation antigen (BCMA)–targeted therapy.

The Data - Arm B of the open-label, Phase Ib MOVISO study (NCT05650632) evaluated

etentamig in patients with r/r MM with ≥2 prior lines of therapy, including triple-class and prior

anti-BCMA exposure.